A Novel Aurora-A Inhibitor (MLN8237) Synergistically Enhances the Antitumor Activity of Sorafenib in Hepatocellular Carcinoma

[1]  Yong Yang,et al.  Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT , 2018, European journal of pharmacology.

[2]  Lei Zhang,et al.  Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway. , 2017, Oncology research.

[3]  B. Zhai,et al.  Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells , 2017, PloS one.

[4]  T. Decaens,et al.  Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma , 2017, Molecular Cancer Therapeutics.

[5]  Lei Lu,et al.  Methylation-associated silencing of microRNA-129-3p promotes epithelial-mesenchymal transition, invasion and metastasis of hepatocelluar cancer by targeting Aurora-A , 2016, Oncotarget.

[6]  G. Schwartz,et al.  Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Sang-Jin Lee,et al.  Dehydrocorydaline promotes myogenic differentiation via p38 MAPK activation , 2016, Molecular medicine reports.

[8]  G. Hu,et al.  Aspafilioside B induces G2/M cell cycle arrest and apoptosis by up‐regulating H‐Ras and N‐Ras via ERK and p38 MAPK signaling pathways in human hepatoma HepG2 cells , 2016, Molecular carcinogenesis.

[9]  P. Babu,et al.  Implications of mitogen‐activated protein kinase signaling in glioma , 2016, Journal of neuroscience research.

[10]  R. Wu,et al.  S100A9 promotes human hepatocellular carcinoma cell growth and invasion through RAGE-mediated ERK1/2 and p38 MAPK pathways. , 2015, Experimental cell research.

[11]  Suresh K Balani,et al.  MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors , 2015, ACS medicinal chemistry letters.

[12]  H. Miyake,et al.  Enhanced sensitivity to sorafenib by inhibition of Akt1 expression in human renal cell carcinoma ACHN cells both in vitro and in vivo , 2015, Human Cell.

[13]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[14]  Chang Liu,et al.  Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1 , 2015, Acta Pharmacologica Sinica.

[15]  Jing Chen,et al.  Aurora-A promotes chemoresistance in hepatocelluar carcinoma by targeting NF-kappaB/microRNA-21/PTEN signaling pathway , 2014, Oncotarget.

[16]  M. Kunnimalaiyaan,et al.  MK2206 inhibits hepatocellular carcinoma cellular proliferation via induction of apoptosis and cell cycle arrest. , 2014, The Journal of surgical research.

[17]  T. Ouchi,et al.  BRAT1 deficiency causes increased glucose metabolism and mitochondrial malfunction , 2014, BMC Cancer.

[18]  A. Godwin,et al.  Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion , 2014, Oncogene.

[19]  I. Lossos,et al.  Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Y. Lei,et al.  Mitogen-activated protein kinase signal transduction in solid tumors. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[21]  W. De,et al.  The role of Aurora A in hypoxia-inducible factor 1α-promoting malignant phenotypes of hepatocelluar carcinoma , 2013, Cell cycle.

[22]  Liang Zhou,et al.  Overexpression of Bmi-1 contributes to the invasion and metastasis of hepatocellular carcinoma by increasing the expression of matrix metalloproteinase (MMP)‑2, MMP-9 and vascular endothelial growth factor via the PTEN/PI3K/Akt pathway. , 2013, International journal of oncology.

[23]  Yitao Wang,et al.  Dehydrocorydaline inhibits breast cancer cells proliferation by inducing apoptosis in MCF-7 cells. , 2012, The American journal of Chinese medicine.

[24]  A. Covey,et al.  Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma , 2012, CA: a cancer journal for clinicians.

[25]  K. Venkatakrishnan,et al.  Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations , 2012, Clinical Cancer Research.

[26]  E. Nagata,et al.  Small molecule-induced cytosolic activation of protein kinase Akt rescues ischemia-elicited neuronal death , 2012, Proceedings of the National Academy of Sciences.

[27]  J. Bruix,et al.  Hepatocellular carcinoma , 2012, The Lancet.

[28]  F. Nevens,et al.  Resistance development after long-term sorafenib exposure in hepatocellular cancer cell lines and risk of rebound growth and epithelial to mesenchymal transition. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  G. Chen,et al.  Induction of autophagy in hepatocellular carcinoma cells by SB203580 requires activation of AMPK and DAPK but not p38 MAPK , 2011, Apoptosis.

[30]  David Olmos,et al.  First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Rachel E. Gershman,et al.  Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays , 2011, Clinical Cancer Research.

[32]  D. Gandara,et al.  Impact of AKT inhibitor MK-2206 on erlotinib resistance in non-small cell lung cancer (NSCLC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  C. Chiu,et al.  p38 MAPK and NF-kappaB pathways are involved in naphtho[1,2-b] furan-4,5-dione induced anti-proliferation and apoptosis of human hepatoma cells. , 2010, Cancer letters.

[34]  Rui Wang,et al.  Expression of STK15 mRNA in hepatocellular carcinoma and its prognostic significance. , 2009, Clinical biochemistry.

[35]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[36]  P. Gao,et al.  Hypoxia‐inducible enhancer/α‐fetoprotein promoter‐driven RNA interference targeting STK15 suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells , 2008, Cancer science.

[37]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[38]  Xin Zhang.  Aurora kinases , 2008, Current Biology.

[39]  Robert E. Brown,et al.  Activation of Akt-mTOR-p70S6K pathway in angiogenesis in hepatocellular carcinoma. , 2008, Oncology reports.

[40]  S. Wilhelm,et al.  Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2006, Nature Reviews Drug Discovery.

[41]  R. Poon,et al.  Molecular pathways in hepatocellular carcinoma. , 2006, Cancer letters.

[42]  H. Saya,et al.  Aurora-A — A guardian of poles , 2005, Nature Reviews Cancer.

[43]  M. Saji,et al.  Overexpression and overactivation of Akt in thyroid carcinoma. , 2001, Cancer research.

[44]  E. Vellenga,et al.  The p38 MAP kinase inhibitor SB203580 enhances nuclear factor‐kappa B transcriptional activity by a non‐specific effect upon the ERK pathway , 2000, British journal of pharmacology.

[45]  R. Reynolds,et al.  Elevated phosphorylation of AKT and Stat3 in prostate, breast, and cervical cancer cells. , 2000, International journal of oncology.

[46]  B. Foxwell,et al.  The Pyridinyl Imidazole Inhibitor SB203580 Blocks Phosphoinositide-dependent Protein Kinase Activity, Protein Kinase B Phosphorylation, and Retinoblastoma Hyperphosphorylation in Interleukin-2-stimulated T Cells Independently of p38 Mitogen-activated Protein Kinase* , 2000, The Journal of Biological Chemistry.

[47]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[48]  G. Wang,et al.  Induction of the , 1996 .